Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
AnaptysbioANAB | Open-market sale | 03/30 | 04/01 | 20,645 sh3 trades | $56.11avg. | $1,158,466.86 | −39.5% | |
AnaptysbioANAB | Open-market sale | 03/27 | 03/27 | 17,679 sh10 trades | $61.61avg. | $1,089,221.59 | −3.4% | |
Eric J. LoumeauChief Legal Officer | AnaptysbioANAB | Open-market sale10b5-1 plan | 02/11 | 02/13 | 10,000 sh | $54.00 | $540,000 | −43.8% |
AnaptysbioANAB | Open-market sale | 01/15 | 01/16 | 11,000 sh2 trades | $48.23avg. | $530,568.3 | −52.6% | |
Eric J. LoumeauChief Legal Officer | AnaptysbioANAB | Open-market sale | 01/08 | 01/09 | 2,210 sh | $44.71 | $98,809.1 | −14.7% |
AnaptysbioANAB | Open-market sale | 01/08 | 01/09 | 2,515 sh | $44.71 | $112,445.65 | −10.3% | |
Daniel FagaPresident, CEO | AnaptysbioANAB | Open-market sale | 01/08 | 01/09 | 14,281 sh | $44.71 | $638,503.51 | −2.9% |
Paul F. LizzulChief Medical Officer | AnaptysbioANAB | Open-market sale | 01/08 | 01/09 | 3,650 sh | $44.71 | $163,191.5 | −8.0% |
AnaptysbioANAB | Open-market sale | 01/07 | 01/08 | 9,639 sh4 trades | $45.56avg. | $439,178.98 | −51.3% | |
AnaptysbioANAB | Open-market sale | 01/07 | 01/08 | 1,908 sh | $45.11 | $86,069.88 | −9.7% | |
Daniel FagaPresident, CEO | AnaptysbioANAB | Open-market sale | 01/07 | 01/08 | 9,202 sh | $45.11 | $415,102.22 | −1.9% |
Paul F. LizzulChief Medical Officer | AnaptysbioANAB | Open-market sale | 01/07 | 01/08 | 2,235 sh | $45.11 | $100,820.85 | −5.7% |
Eric J. LoumeauChief Legal Officer | AnaptysbioANAB | Open-market sale | 01/05 | 01/06 | 2,983 sh | $43.26 | $129,044.58 | −18.4% |
AnaptysbioANAB | Open-market sale | 01/05 | 01/06 | 3,363 sh | $43.26 | $145,483.38 | −19.0% | |
Daniel FagaPresident, CEO | AnaptysbioANAB | Open-market sale | 01/05 | 01/06 | 15,309 sh | $43.26 | $662,267.34 | −3.2% |
Paul F. LizzulChief Medical Officer | AnaptysbioANAB | Open-market sale | 01/05 | 01/06 | 4,219 sh | $43.26 | $182,513.94 | −11.2% |
J. Anthony WareDirector | AnaptysbioANAB | Open-market sale | 25/12/23 | 25/12/23 | 3,900 sh | $49.58 | $193,362 | −28.8% |
Eric J. LoumeauChief Legal Officer | AnaptysbioANAB | Open-market sale10b5-1 plan | 25/12/22 | 25/12/23 | 10,000 sh | $51.00 | $510,000 | −52.8% |
AnaptysbioANAB | Open-market sale10b5-1 plan | 25/12/22 | 25/12/23 | 10,000 sh | $50.00 | $500,000 | −51.5% | |
Paul F. LizzulChief Medical Officer | AnaptysbioANAB | Open-market sale10b5-1 plan | 25/12/22 | 25/12/23 | 1,500 sh | $50.00 | $75,000 | −5.3% |
